Every day, approximately 180 liters of blood are filtered by your kidneys, extracting waste while preserving substances your body needs. When this system begins to fail, it often does so subtly. Proteins start leaking into urine, the filtration rate diminishes, and once this decline commences, it usually persists. For many patients, doctors have had limited options to counter this decline, mainly relying on standard blood-pressure medications. However, a new possibility has emerged.<\/p>\n
A medication known as finerenone, already authorized for patients with kidney disease resulting from type 2 diabetes, has recently been demonstrated to slow this decline in individuals without diabetes. This is a noteworthy development because more than half of the chronic kidney disease cases worldwide are not diabetes-related.<\/p>\n
The findings originate from the FIND-CKD trial, the largest phase III study addressing non-diabetic kidney disease, with results published in the New England Journal of Medicine and presented at the European Renal Association congress in Glasgow. Researchers randomly assigned 1,584 adults, all receiving standard renin-angiotensin system blockers, to daily doses of either finerenone or a placebo. Participants were monitored for an average of just over three years to evaluate kidney function. Finerenone acts as a nonsteroidal mineralocorticoid receptor antagonist, which helps mitigate hormonal signals that lead to inflammation and damage in the kidneys.<\/p>\n
The primary statistic is modest but significant. Kidney function, measured by the estimated glomerular filtration rate (eGFR), declined by approximately 3.3 units per year in the finerenone group, compared to around 4.0 in the placebo group. Although a difference of 0.7 per year may appear minor, over several decades, it can postpone the necessity for dialysis or a transplant.<\/p>\n
An Established Medication, a Diverse Group<\/p>\n
The research team was not taken aback by the magnitude of effect but rather by its range. The trial included individuals with kidney damage due to hypertension, glomerular diseases, and various underlying conditions exclusive to a failing organ with few therapeutic choices. \u201cIt turns out the drug is also effective in individuals without diabetes, despite more than half of CKD patients globally being non-diabetic,\u201d states Hiddo Lambers Heerspink, a clinical pharmacologist at the University Medical Center Groningen who oversaw the study. \u201cChronic kidney disease now impacts around 800 million adults worldwide.\u201d<\/p>\n
The advantages extended beyond the filtration rate. Finerenone also lowered the likelihood of severe composite outcomes, including kidney failure, hospitalization for heart failure, or cardiovascular-related death. \u201cIn the finerenone group, 13.9 percent experienced such complications, in contrast to 16.9 percent in the placebo group,\u201d notes Lambers Heerspink. \u201cThis represents a risk reduction of about 23 percent.\u201d<\/p>\n
Moreover, finerenone significantly decreased albuminuria, an early sign of kidney issues. \u201cIn the finerenone group, it dropped by an average of over 41 percent, while the placebo group saw about a 9 percent change,\u201d remarks Lambers Heerspink, adding that over half of the individuals on the medication experienced a urinary protein reduction of at least 30 percent, suggesting a more favorable long-term prognosis.<\/p>\n
The Downside, and It Is Real<\/p>\n
No medication is free of side effects. The most prevalent was hyperkalaemia, an excess of potassium in the bloodstream that can disturb heart rhythm. It occurred in 17 percent of those on finerenone compared to 13.3 percent on placebo. This was largely manageable; only about 1.5 percent needed to discontinue the drug, and hospitalizations for the issue were infrequent in both groups. Acute kidney injury, a substantial concern for kidney treatments, appeared at similar rates among both cohorts.<\/p>\n
Caution is advisable as the study was funded by Bayer, the manufacturer of finerenone, and while analyses were independently validated, the 0.7-unit deceleration as the headline outcome is modest. Whether regulatory bodies and guideline committees deem it adequate for a new indication remains a separate discussion from the soundness of the biological principles.<\/p>\n
Nonetheless, for a patient demographic that is frequently neglected by guidelines, this alters the treatment paradigm. \u201cFinerenone could emerge as a vital new treatment choice for individuals with chronic kidney disease who do not have diabetes,\u201d states Lambers Heerspink, emphasizing \u201ca broad, underserved patient population with non-diabetic CKD, for whom the treatment options in the guidelines are few.\u201d For nearly a billion individuals with gradually deteriorating kidney function, this progress is meaningful. The next slide may have just become a bit less steep.<\/p>\n
Source: [New England Journal of Medicine, DOI 10.1056\/NEJMoa2604625](https:\/\/doi.org\/10.1056\/NEJMoa2604625)<\/p>\n","protected":false},"excerpt":{"rendered":"
Every day, approximately 180 liters of blood are filtered by your kidneys, extracting waste while preserving substances your body needs. When this system begins to fail, it often does so subtly. Proteins start leaking into urine, the filtration rate diminishes, and once this decline commences, it usually persists. For many patients, doctors have had limited […]<\/p>\n","protected":false},"author":1,"featured_media":372912,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"Default","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[179],"class_list":["post-372911","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","tag-source-scienceblog-com"],"_links":{"self":[{"href":"https:\/\/wolfscientific.com\/index.php?rest_route=\/wp\/v2\/posts\/372911","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wolfscientific.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wolfscientific.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/wolfscientific.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/wolfscientific.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=372911"}],"version-history":[{"count":0,"href":"https:\/\/wolfscientific.com\/index.php?rest_route=\/wp\/v2\/posts\/372911\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wolfscientific.com\/index.php?rest_route=\/wp\/v2\/media\/372912"}],"wp:attachment":[{"href":"https:\/\/wolfscientific.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=372911"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wolfscientific.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=372911"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wolfscientific.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=372911"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}